Drug
Zervimesine clinical trials
Also written CT1812.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2015
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
10 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 2 |
| 2018 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 0
Cognition Therapeutics (10)
Often tested with
Tested in the same studies.
Tolbutamide (1) · Dextromethorphan (1) · Omeprazole (1) · Midazolam (1)
Studies
Open first, then newest update. How each study uses zervimesine is read from its arms, and is right about nine times in ten.
Testing it · 10
- A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's DiseaseActive, not recruitingPhase 2Cognition TherapeuticsNCT05531656Written as CT1812
- Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy BodiesCompletedPhase 2Cognition TherapeuticsNCT05225415Written as CT1812
- A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.CompletedPhase 2Cognition TherapeuticsNCT03507790Written as CT1812
- Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEGCompletedPhase 2Cognition TherapeuticsNCT04735536Written as CT1812
- Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male SubjectsCompletedPhase 1Cognition TherapeuticsNCT05225389Written as 300 mg [C14] CT1812
- Study to Assess the Pharmacokinetics of CT1812 in Older Healthy VolunteersCompletedPhase 1Cognition TherapeuticsNCT05248672Written as CT1812
- Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's DiseaseCompletedPhase 1Cognition TherapeuticsNCT03522129Written as CT1812
- Drug Interaction Study of CT1812 in Healthy VolunteersCompletedPhase 1Cognition TherapeuticsNCT03716427Written as CT1812
- Clinical Trial of CT1812 in Mild to Moderate Alzheimer's DiseaseCompletedPhase 1/2Cognition TherapeuticsNCT02907567Written as CT1812
- Ascending Dose Study of CT1812 in Healthy VolunteersCompletedPhase 1Cognition TherapeuticsNCT02570997Written as CT1812
Codes
What other systems call zervimesine · ClinicalTrials.gg INT014163
- UNII (FDA) 0661V34NTVZERVIMESINEConfirmed FDA, Wikidata
- Wikidata Q135688895zervimesineConfirmed FDA, Wikidata
- NCI Thesaurus C215787ZervimesineOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 0661V34NTV | ZERVIMESINE | Confirmed FDA, Wikidata |
| Wikidata | Q135688895 | zervimesine | Confirmed FDA, Wikidata |
| NCI Thesaurus | C215787 | Zervimesine | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.